research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Editorial: Exploring innovative therapies for rare inflammatory skin diseases
New therapies for rare skin diseases show promise but need more research.
research Tangled Causes, Targeted Solutions: A Comprehensive Review of Alopecia.
Alopecia is caused by various factors, and new treatments like gene editing and regenerative medicine offer hope for personalized hair regrowth solutions.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
64 drugs can cause hair loss, needing better monitoring and updated labels.
research Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
Alopesi tedavisinde ilaçlar saç büyümesini teşvik eder ve yeni yaklaşımlar umut vaat eder.
research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Consider Cultural Practices and Barriers to Care When Treating Alopecia Areata
Consider cultural practices and barriers for effective alopecia areata treatment.
research Th1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
research Past, Present and Future Treatment of Alopecia Areata
More research is needed to find the best long-term treatments for Alopecia Areata.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Copper−Doxorubicin as a Nanoparticle Cargo Retains Efficacy with Minimal Toxicity
Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
research Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research Dauricine attenuates Oct4/sonic hedgehog co‐activated stemness and induces reactive oxygen species‐mediated mitochondrial apoptosis via AKT /β‐catenin signaling in human neuroblastoma and glioblastoma stem‐like cells
Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.
research Myeloproliferative disorder associated with alopecia universalis
Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.